Alexander I. Spira, MD, PhD, FACP, Provides an Overview of the Use of Adagrasib in Advanced KRAS G12C–Mutant NSCLC at ASCO 2022

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Annual Meeting, Alexander I. Spira, MD, PhD, FACP, a medical oncologist and co-director of the Virginia Cancer Specialists Research Institution, and director of the Thoracic and Phase I Program and clinical assistant professor at Johns Hopkin, discusses the safety profile of adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C–mutated non–small cell lung cancer from the phase 1/2 KRYSTAL-1 trial (NCT03785249). Moreover, Spira highlighted future analyses and research that are underway to further evaluated adagrasib within this patient population.

Watch the interview, and see the transcript at